SUZANNE GAZDA M.D.
  • Home
  • Meet Dr. Gazda
    • Our Practice
  • Lectures/Videos
  • BLOGS
    • Blog - Long Covid
    • Blog - NEUROLOGY TRENDS
    • Blog - MS in the NEWS
    • Blog - Scientifically Speaking
    • Blog - Guest Articles
  • Our Approach
  • Conditions we treat
    • Alzheimer’s Disease
    • Amyotrophic Lateral Sclerosis (ALS)
    • Long COVID
    • Multiple Sclerosis (MS)
    • PANS | PANDAS
    • Parkinson’s disease
  • Treatment Protocols
  • Patient Stories
  • FAQ
  • Policies & Rates
  • Helpful LInks
  • Medical Resources
  • Journal Articles
  • Product Recommendations
  • Become a Patient
  • NEWS
  • Contact

Scientifically Speaking

Low levels of IgG in MS patients.

1/24/2020

1 Comment

 
Picture
This recent study showed that patients with multiple sclerosis (MS) have reduced IgG levels, while prior studies also showed a link to other types of autoimmune diseases and similar low IgG levels. We need to ask why this matters and why does this occur? And just as important, what can we do with this new information to positively impact our treatment approaches? 


Read More
1 Comment

Mold is bad news for the brain.

1/19/2020

15 Comments

 
Picture
In a recent journal published in Brain, Behavior and Immunity* we can truly see how mold is bad news for the brain. In this study they dripped Stachybotrys fungi into the nose of rats   (can’t imagine having this job!) and found within a short period of time hippocampal immune activation, decreased memory and striking anxiety and as well reduced levels of dopamine .   


Read More
15 Comments

Minocycline Trial for Alzheimer’s disease yields disappointing results.

1/3/2020

1 Comment

 
Picture
Update, July 2020…re: new information about minocycline.
Interesting new research has come to light since we last wrote about minocycline, a medication that has been around for quite some time (actually, about 50 years!) and is commonly prescribed to treat bacterial infections.

As previously discussed in our first blog that follows here, the dosage used in the Alzheimer’s disease trials was 200-400mg per day, but not many patients were able to tolerate this for very long due to gastrointestinal side effects.

Read More
1 Comment

    Author

    by Suzanne Gazda M.D.
    Here you’ll find a collection of articles and information from a more-scientific perspective about many aspects of the neurological conditions we treat at Gazda Integrative Neurology.
    Please check back often as new items are regularly added.

    Archives

    August 2021
    February 2021
    January 2021
    November 2020
    October 2020
    August 2020
    July 2020
    May 2020
    April 2020
    January 2020
    November 2019
    October 2019

    Categories

    All

    RSS Feed

SITE MAP

HOME
MEET DR. GAZDA
OUR PRACTICE
INTEGRATIVE MEDICINE
OUR APPROACH
CONDITIONS WE TREAT
TREATMENT PROTOCOLS
PATIENT STORIES
FAQ
POLICIES & RATES
BLOG
SCIENTIFICALLY SPEAKING
MEDICAL RESOURCES
JOURNAL ARTICLES
LINKS
BECOME A PATIENT
CONTACT
NEWS
PRODUCT RECOMMENDATIONS

Location

San Antonio, Texas

Telephone

210-692-1245
Fax
210-692-9311

Email

[email protected]
  • Home
  • Meet Dr. Gazda
    • Our Practice
  • Lectures/Videos
  • BLOGS
    • Blog - Long Covid
    • Blog - NEUROLOGY TRENDS
    • Blog - MS in the NEWS
    • Blog - Scientifically Speaking
    • Blog - Guest Articles
  • Our Approach
  • Conditions we treat
    • Alzheimer’s Disease
    • Amyotrophic Lateral Sclerosis (ALS)
    • Long COVID
    • Multiple Sclerosis (MS)
    • PANS | PANDAS
    • Parkinson’s disease
  • Treatment Protocols
  • Patient Stories
  • FAQ
  • Policies & Rates
  • Helpful LInks
  • Medical Resources
  • Journal Articles
  • Product Recommendations
  • Become a Patient
  • NEWS
  • Contact